Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 27

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 27
---
 from the offering for general corporate purposes, including working capital.

Supply Chain Updates

In February 2025, the FDA authorized the importation
of Kodatef from Australia, to cover any future disruption of Arakoda in the U.S. market. Kodatef is the branded version of tafenoquine
for malaria prevention approved by the TGA for use in Australia. The Company made this request of the FDA due to robust demand for Arakoda
in late 2024/early 2025, and the potential for delays in the completion of new lots of Arakoda currently being commercially validated
by our key supplier, PCI. Although we anticipate that new commercial Arakoda lots will enter the supply chain prior to the exhaustion
of existing inventory, Kodatef will be available to cover any shortage through a specialty pharmacy that already carries Arakoda, and
has the capacity to ship to customers in all 50 states.

IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

On January 8, 2025, we announced that the approval
of an Investigational Review Board (IRB) sanctioned Phase II clinical study. The study (NCT06656351) will evaluate the efficacy and safety
of the ARAKODA® regimen (tafenoquine) over 90 days for treating patients with a presumptive diagnosis of chronic babesiosis who have
experienced severe fatigue with significant functional impairment for at least six months upon enrollment. Patient enrollment is expected
to begin in the third quarter of 2025.

First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

On January 8, 2025, we announced that the first
patient has been enrolled in NCT06478641, an expanded access clinical study intended to confirm the activity of tafenoquine in treating
patients with persistent babesiosis who have failed standard of care treatment and are at high risk of experiencing a relapse.

<div align='center'>S-15</div>

ATM Offering

On July 12, 2024, we entered into an At-the-Market
Issuance Sales Agreement (the “ATM Agreement”) with WallachBeth Capital LLC (“WallachBeth”) to sell shares of
Common Stock having an aggregate offering price of up to $1,253,603 from time to time, through an “at the market offering”
program (the “ATM Offering